You are viewing the site in preview mode

Skip to main content

Advertisement

Basic Tumor Immunology

Section edited by Cornelis J.M. Melief, MD, PhD

Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.

Page 1 of 3

  1. Content type: Research article

    Efficient cancer therapy is sought not only for primary tumor treatment but also for the prevention of metastatic cancer growth. Immunotherapy has been shown to prevent cancer metastasis by inducing antigen-sp...

    Authors: Li Xu, Wei Zhang, Hae-Bin Park, Minseok Kwak, Junghwan Oh, Peter C. W. Lee and Jun-O Jin

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:220

    Published on:

  2. Content type: Research article

    The clinical benefit of immunotherapeutic approaches against cancer has been well established although complete responses are only observed in a minority of patients. Combination immunotherapy offers an attrac...

    Authors: Guillaume Beyrend, Esmé van der Gracht, Ayse Yilmaz, Suzanne van Duikeren, Marcel Camps, Thomas Höllt, Anna Vilanova, Vincent van Unen, Frits Koning, Noel F. C. C. de Miranda, Ramon Arens and Ferry Ossendorp

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:217

    Published on:

  3. Content type: Research article

    Immune checkpoint inhibitors (ICIs) for solid tumors, including those targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have shown impressive clinical efficacy,...

    Authors: Jared M. Newton, Aurelie Hanoteau, Hsuan-Chen Liu, Angelina Gaspero, Falguni Parikh, Robyn D. Gartrell-Corrado, Thomas D. Hart, Damya Laoui, Jo A. Van Ginderachter, Neeraja Dharmaraj, William C. Spanos, Yvonne Saenger, Simon Young and Andrew G. Sikora

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:216

    Published on:

  4. Content type: Research article

    Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development...

    Authors: Suzanne Thomas, Linta Kuncheria, Victoria Roulstone, Joan N. Kyula, David Mansfield, Praveen K. Bommareddy, Henry Smith, Howard L. Kaufman, Kevin J. Harrington and Robert S. Coffin

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:214

    Published on:

  5. Content type: Research article

    Colorectal cancer (CRC) is one of the most common forms of cancer worldwide. The tumor microenvironment plays a key role in promoting the occurrence of chemoresistance in solid cancers. Effective targets to ov...

    Authors: Dan Wang, Li Yang, Weina Yu, Qian Wu, Jingyao Lian, Feng Li, Shasha Liu, Aitian Li, Zhiang He, Jinbo Liu, Zhenqiang Sun, Weitang Yuan and Yi Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:215

    Published on:

  6. Content type: Research article

    Indoleamine 2,3-dioxygenase 1 (IDO1) is a critical regulator of T cell function, contributing to immune tolerance. Upregulation of IDO1 has been found in many cancer types; however, the regulatory mechanisms a...

    Authors: Qiong Lou, Ruixian Liu, Xiangling Yang, Weiqian Li, Lanlan Huang, Lili Wei, Huiliu Tan, Nanlin Xiang, Kawo Chan, Junxiong Chen and Huanliang Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:210

    Published on:

  7. Content type: Research article

    Blocking programmed death-1 (PD-1) is considered to be a promising strategy to improve T cell function, and this is being explored in many ongoing clinical trials. In fact, our knowledge about PD-1 is primaril...

    Authors: Jianshu Wei, Can Luo, Yao Wang, Yelei Guo, Hanren Dai, Chuan Tong, Dongdong Ti, Zhiqiang Wu and Weidong Han

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:209

    Published on:

  8. Content type: Research article

    NKT cells play an important role in anti-tumor immunity. Alpha-galactosylceramide (α-GalCer), a synthetic glycolipid is presented to natural killer T (NKT) cells by most antigen-presenting cells through CD1d m...

    Authors: Sourav Paul, Sushanta Chhatar, Amrita Mishra and Girdhari Lal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:208

    Published on:

  9. Content type: Research article

    One of the mechanisms by which tumors evade immune surveillance is through shedding of the major histocompatibility complex (MHC) class I chain-related protein A and B (MICA/B) from their cell surface. MICA/B ...

    Authors: Changchun Du, Jack Bevers III, Ryan Cook, T. Noelle Lombana, Kamalakannan Rajasekaran, Marissa Matsumoto, Christoph Spiess, Jeong M. Kim and Zhengmao Ye

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:207

    Published on:

  10. Content type: Research article

    Interleukin(IL)-30/IL-27p28 production by Prostate Cancer (PC) Stem-Like Cells (SLCs) has proven, in murine models, to be critical to tumor onset and progression. In PC patients, IL-30 expression by leukocytes...

    Authors: Carlo Sorrentino, Zhinan Yin, Stefania Ciummo, Paola Lanuti, Li-Fan Lu, Marco Marchisio, Matteo Bellone and Emma Di Carlo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:201

    Published on:

  11. Content type: Research article

    Despite major advancements in immunotherapy among a number of solid tumors, response rates among ovarian cancer patients remain modest. Standard treatment for ovarian cancer is still surgery followed by taxane...

    Authors: Christina A. Hartl, Adrian Bertschi, Regina Bou Puerto, Carolin Andresen, Emily M. Cheney, Elizabeth A. Mittendorf, Jennifer L. Guerriero and Michael S. Goldberg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:199

    Published on:

  12. Content type: Research article

    Innate immune cells such as macrophages are abundantly present within malignant ascites, where they share the microenvironment with ovarian cancer stem cells (CSC).

    Authors: Shreya Raghavan, Pooja Mehta, Yuying Xie, Yu L. Lei and Geeta Mehta

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:190

    Published on:

  13. Content type: Research article

    Micro(mi)RNAs are increasingly recognized as central regulators of immune cell function. While it has been predicted that miRNAs have multiple targets, the majority of these predictions still await experimenta...

    Authors: Martin Hart, Barbara Walch-Rückheim, Lena Krammes, Tim Kehl, Stefanie Rheinheimer, Tanja Tänzer, Birgit Glombitza, Martina Sester, Hans-Peter Lenhof, Andreas Keller and Eckart Meese

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:187

    Published on:

  14. Content type: Research article

    Limitations to current therapies for treating non-Hodgkin B cell lymphoma include relapse, toxicity and high cost. Thus, there remains a need for novel therapies. Oncolytic viral (OV) therapy has become a prom...

    Authors: Minjun Yu, Iris Scherwitzl, Silvana Opp, Aristotelis Tsirigos and Daniel Meruelo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:185

    Published on:

  15. Content type: Research article

    CD4+ T cells are critical effectors of anti-tumor immunity, but how tumor cells influence CD4+ T cell effector function is not fully understood. Tumor cell-released autophagosomes (TRAPs) are being recognized as ...

    Authors: Yong-Qiang Chen, Peng-Cheng Li, Ning Pan, Rong Gao, Zhi-Fa Wen, Tian-Yu Zhang, Fang Huang, Fang-Yuan Wu, Xi-Long Ou, Jin-Ping Zhang, Xue-Jun Zhu, Hong-Ming Hu, Kang Chen, Yun-Lang Cai and Li-Xin Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:178

    Published on:

  16. Content type: Research article

    Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches t...

    Authors: Deborah Ayeni, Braden Miller, Alexandra Kuhlmann, Ping-Chih Ho, Camila Robles-Oteiza, Mmaserame Gaefele, Stellar Levy, Fernando J. de Miguel, Curtis Perry, Tianxia Guan, Gerald Krystal, William Lockwood, Daniel Zelterman, Robert Homer, Zongzhi Liu, Susan Kaech…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:172

    Published on:

  17. Content type: Research article

    Traditional therapies fail to cure most glioblastoma patients and the 5-year survival rate is less than 10%, highlighting need for new therapeutic approaches. The natural killer group 2 member D ligands (NKG2D...

    Authors: Dong Yang, Bin Sun, Hongjiu Dai, Wenxuan Li, Lan Shi, Peixian Zhang, Shirong Li and Xudong Zhao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:171

    Published on:

  18. Content type: Research article

    Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. Clinica...

    Authors: Mathieu Grapin, Corentin Richard, Emeric Limagne, Romain Boidot, Véronique Morgand, Aurélie Bertaut, Valentin Derangere, Pierre-Antoine Laurent, Marion Thibaudin, Jean David Fumet, Gilles Crehange, François Ghiringhelli and Céline Mirjolet

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:160

    Published on:

  19. Content type: Research article

    Type I interferons (IFN-I) have recently emerged as key regulators of tumor response to chemotherapy and immunotherapy. However, IFN-I function in cytotoxic T lymphocytes (CTLs) in the tumor microenvironment i...

    Authors: Chunwan Lu, John D. Klement, Mohammed L. Ibrahim, Wei Xiao, Priscilla S. Redd, Asha Nayak-Kapoor, Gang Zhou and Kebin Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:157

    Published on:

  20. Content type: Short report

    PD-1 inhibitors are approved for multiple malignancies and function by stimulating T cells. However, the role of B cells in the anti-tumor activity of these drugs is unknown, as is their activity in patients w...

    Authors: William Damsky, Lucia Jilaveanu, Noel Turner, Curtis Perry, Christopher Zito, Mary Tomayko, Jonathan Leventhal, Kevan Herold, Eric Meffre, Marcus Bosenberg and Harriet M. Kluger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:153

    Published on:

  21. Content type: Research article

    T-cell mediated immunotherapy brought clinical success for many cancer patients. Nonetheless, downregulation of MHC class I antigen presentation, frequently occurring in solid cancers, limits the efficacy of t...

    Authors: Koen A. Marijt, Marjolein Sluijter, Laura Blijleven, Sofie H. Tolmeijer, Ferenc A. Scheeren, Sjoerd H. van der Burg and Thorbald van Hall

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:152

    Published on:

  22. Content type: Research article

    Binding of the programmed death-1 (PD-1) receptor to its ligands (PD-L1/2) transduces inhibitory signals that promote exhaustion of activated T cells. Blockade of the PD-1 pathway is widely used for cancer tre...

    Authors: Jesús Ogando, María Eugenia Sáez, Javier Santos, Cristina Nuevo-Tapioles, Marta Gut, Anna Esteve-Codina, Simon Heath, Antonio González-Pérez, José M. Cuezva, Rosa Ana Lacalle and Santos Mañes

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:151

    Published on:

  23. Content type: Research article

    Tumor-associated macrophages (TAMs) are the major component of tumor-infiltrating immune cells. Macrophages are broadly categorized as M1 or M2 types, and TAMs have been shown to express an M2-like phenotype. ...

    Authors: Chanju Lee, Hyunju Jeong, Younghyeon Bae, Kyungmoon Shin, Sinwoo Kang, Hwikyung Kim, Jayoung Oh and Hyunsu Bae

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:147

    Published on:

  24. Content type: Research article

    Tumor-associated macrophages (TAM) are expanded and exhibit tumor-promoting properties within the tumor microenvironment. Current methods to study TAM have not been replicated across cancer types and often do ...

    Authors: Brooke Benner, Luke Scarberry, Lorena P. Suarez-Kelly, Megan C. Duggan, Amanda R. Campbell, Emily Smith, Gabriella Lapurga, Kallie Jiang, Jonathan P. Butchar, Susheela Tridandapani, John Harrison Howard, Robert A. Baiocchi, Thomas A. Mace and William E. Carson III

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:140

    Published on:

  25. Content type: Research article

    Targeting epitopes derived from neo-antigens (or “neo-epitopes”) represents a promising immunotherapy approach with limited off-target effects. However, most peptides predicted using MHC binding prediction alg...

    Authors: Hanan Besser, Sharon Yunger, Efrat Merhavi-Shoham, Cyrille J. Cohen and Yoram Louzoun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:135

    Published on:

  26. Content type: Short report

    High-risk human papillomavirus (HPV) are responsible for genital and oral cancers associated with the expression of the E6/E7 HPV oncogenes. Therapeutic vaccines targeting those oncogenes can only partially co...

    Authors: Sonia Domingos-Pereira, Gabriele Galliverti, Douglas Hanahan and Denise Nardelli-Haefliger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:122

    Published on:

  27. Content type: Research article

    Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates a barrier to therapy. A murine transgenic pancreatic cancer cell line that recapitulates human disease was used to test...

    Authors: Weiqing Jing, Donna McAllister, Emily P. Vonderhaar, Katie Palen, Matthew J. Riese, Jill Gershan, Bryon D. Johnson and Michael B. Dwinell

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:115

    Published on:

  28. Content type: Research article

    Induction of strong T cell responses, in particular cytotoxic T cells, is a key for the generation of efficacious therapeutic cancer vaccines which yet, remains a major challenge for the vaccine developing wor...

    Authors: Mona O. Mohsen, Matthew D. Heath, Gustavo Cabral-Miranda, Cyrill Lipp, Andris Zeltins, Marcos Sande, Jens V. Stein, Carsten Riether, Elisa Roesti, Lisha Zha, Paul Engeroff, Aadil El-Turabi, Thomas M. Kundig, Monique Vogel, Murray A. Skinner, Daniel E. Speiser…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:114

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:137

  29. Content type: Research article

    Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance...

    Authors: Marjolaine Debant, Miguel Burgos, Patrice Hemon, Paul Buscaglia, Tinhinane Fali, Sarra Melayah, Nelig Le Goux, Christophe Vandier, Marie Potier-Cartereau, Jacques-Olivier Pers, Adrian Tempescul, Christian Berthou, Cristina Bagacean, Olivier Mignen and Yves Renaudineau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:111

    Published on:

  30. Content type: Research article

    The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential, despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies...

    Authors: Stefanie K. Wculek, Joaquín Amores-Iniesta, Ruth Conde-Garrosa, Sofía C. Khouili, Ignacio Melero and David Sancho

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:100

    Published on:

  31. Content type: Research article

    Notch intercellular communication instructs tissue-specific T-cell development and function. In this study, we explored the roles of dendritic cell (DC)-expressed Notch ligands in the regulation of T-cell effe...

    Authors: Elena E. Tchekneva, Mounika U.L. Goruganthu, Roman V. Uzhachenko, Portia L. Thomas, Anneliese Antonucci, Irina Chekneva, Michael Koenig, Longzhu Piao, Anwari Akhter, Maria Teresa P. de Aquino, Parvathi Ranganathan, Nicholas Long, Thomas Magliery, Anna Valujskikh, Jason V. Evans, Rajeswara R. Arasada…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:95

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:124

  32. Content type: Research article

    Low availability of oxygen in tumors contributes to the hostility of the tumor microenvironment toward the immune system. However, the dynamic relationship between local oxygen levels and the immune surveillan...

    Authors: Mateusz Rytelewski, Karine Haryutyunan, Felix Nwajei, Meenakshi Shanmugasundaram, Patrick Wspanialy, M. Anna Zal, Chao-Hsien Chen, Mirna El Khatib, Shane Plunkett, Sergei A. Vinogradov, Marina Konopleva and Tomasz Zal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:78

    Published on:

  33. Content type: Short report

    Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sough...

    Authors: Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J. Philip, Jo Ann Hsu, Nazli Dizman, Ulka Vaishampayan, Tanya Dorff and Sumanta Kumar Pal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:71

    Published on:

  34. Content type: Research article

    Tumor progression is accompanied by dramatic remodeling of the surrounding extracellular matrix leading to the formation of a tumor-specific ECM, which is often more collagen-rich and of increased stiffness. T...

    Authors: Dorota E. Kuczek, Anne Mette H. Larsen, Marie-Louise Thorseth, Marco Carretta, Adrija Kalvisa, Majken S. Siersbæk, Ana Micaela C. Simões, Anne Roslind, Lars H. Engelholm, Elfriede Noessner, Marco Donia, Inge Marie Svane, Per thor Straten, Lars Grøntved and Daniel H. Madsen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:68

    Published on:

  35. Content type: Research article

    Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human pati...

    Authors: E. Dodagatta-Marri, D. S. Meyer, M. Q. Reeves, R. Paniagua, M. D. To, M. Binnewies, M. L. Broz, H. Mori, D. Wu, M. Adoumie, R. Del Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:62

    Published on:

  36. Content type: Research article

    Immunogenic radiotherapy (RT) can act synergistically with immune checkpoint blockers (ICBs). However, alternatives are needed for non-responding patients and those with pre-existing or ICB-induced autoimmune ...

    Authors: Hua Jing, Michael Hettich, Simone Gaedicke, Elke Firat, Mark Bartholomä and Gabriele Niedermann

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:55

    Published on:

  37. Content type: Research article

    Mast cells are prominent components of solid tumors and exhibit distinct phenotypes in different tumor microenvironments. However, the nature, regulation, function, and clinical relevance of mast cells in huma...

    Authors: Yipin Lv, Yongliang Zhao, Xianhua Wang, Na Chen, Fangyuan Mao, Yongsheng Teng, Tingting Wang, Liusheng Peng, Jinyu Zhang, Ping Cheng, Yugang Liu, Hui Kong, Weisan Chen, Chuanjie Hao, Bin Han, Qiang Ma…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:54

    Published on:

  38. Content type: Research article

    The development of memory responses is an evolutionary function of the adaptive immune system. We propose that for the immune system to populate the memory compartment with the best-suited CD8 T cells it utili...

    Authors: Cynthia Perez, Kushal Prajapati, Brianna Burke, Lourdes Plaza-Rojas, Nancy J. Zeleznik-Le and Jose A. Guevara-Patino

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:48

    Published on:

  39. Content type: Research article

    The thymic stromal lymphopoietin (TSLP), a key cytokine for development of Th2 immunity, is produced by cancer associated fibroblasts (CAFs) in pancreatic cancer where predominant tumor infiltrating Th2 over T...

    Authors: Emanuela Brunetto, Lucia De Monte, Gianpaolo Balzano, Barbara Camisa, Vincenzo Laino, Michela Riba, Silvia Heltai, Marco Bianchi, Claudio Bordignon, Massimo Falconi, Attilio Bondanza, Claudio Doglioni and Maria Pia Protti

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:45

    Published on:

  40. Content type: Research article

    Cervical cancer (CxCa) is mainly a locally invading disease that metastasizes to loco-regional lymph node basins before involving distant organs in more advanced stages. Local immune potentiation of tumor-drai...

    Authors: A. M. Heeren, J. Rotman, A. G. M. Stam, N. Pocorni, A. A. Gassama, S. Samuels, M. C. G. Bleeker, C. H. Mom, H. J. M. A. A. Zijlmans, G. G. Kenter, E. S. Jordanova and T. D. de Gruijl

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:43

    Published on:

  41. Content type: Research article

    The role of programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) in triple negative breast cancer (TNBC) remains to be fully understood. In this study, we investigated the role of PD-1...

    Authors: Joe Yeong, Jeffrey Chun Tatt Lim, Bernett Lee, Huihua Li, Clara Chong Hui Ong, Aye Aye Thike, Wei Hseun Yeap, Yi Yang, Ansel Yi Herh Lim, Timothy Kwang Yong Tay, Jin Liu, Siew-Cheng Wong, Jinmiao Chen, Elaine Hsuen Lim, Jabed Iqbal, Rebecca Dent…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:34

    Published on:

  42. Content type: Research article

    Tumor orchestrated metabolic changes in the microenvironment limit generation of anti-tumor immune responses. Availability of arginine, a semi-essential amino acid, is critical for lymphocyte proliferation and...

    Authors: Juan J. Miret, Paul Kirschmeier, Shohei Koyama, Mingrui Zhu, Yvonne Y. Li, Yujiro Naito, Min Wu, Venkat S. Malladi, Wei Huang, William Walker, Sangeetha Palakurthi, Glenn Dranoff, Peter S. Hammerman, Chad V. Pecot, Kwok-Kin Wong and Esra A. Akbay

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:32

    Published on:

  43. Content type: Research article

    Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunothe...

    Authors: Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, Lindsay B. Alcaraz, Pascal Roger, Séverine Guiu, Danielle Derocq, Gautier Robin, Henri-Alexandre Michaud, Helène Delpech, Marta Jarlier, Martine Pugnière, Bruno Robert, Anthony Puel, Lucie Martin, Flavie Landomiel…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:29

    Published on:

  44. Content type: Research article

    Tumor specific Th9 cells are potential effector cells for adoptive therapy of human cancers. TNF family members OX40L, TL1A and GITRL have been shown to promote the induction of Th9 cells and antitumor immunit...

    Authors: Yuxue Jiang, Jintong Chen, Enguang Bi, Yinghua Zhao, Tianxue Qin, Yiming Wang, Alison Wang, Sujun Gao, Qing Yi and Siqing Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:28

    Published on:

  45. Content type: Research article

    The capacity of cytomegalovirus (CMV) to elicit long-lasting strong T cell responses, and the ability to engineer the genome of this DNA virus positions CMV-based vaccine vectors highly suitable as a cancer va...

    Authors: Elham Beyranvand Nejad, Robert B. Ratts, Eleni Panagioti, Christine Meyer, Jennifer D. Oduro, Luka Cicin-Sain, Klaus Früh, Sjoerd H. van der Burg and Ramon Arens

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:25

    Published on:

  46. Content type: Research article

    Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a n...

    Authors: Lucia D’Amico, Ulrike Menzel, Michael Prummer, Philipp Müller, Mélanie Buchi, Abhishek Kashyap, Ulrike Haessler, Alexander Yermanos, Rémy Gébleux, Manfred Briendl, Tamara Hell, Fabian I. Wolter, Roger R. Beerli, Iva Truxova, Špíšek Radek, Tatjana Vlajnic…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:16

    Published on:

  47. Content type: Research article

    Regulatory T cells (Tregs) may comprise different subsets allowing them to efficiently suppress different types of effector T cells. In this study, we show that high numbers of both conventional and Tbet co-ex...

    Authors: S. J. Santegoets, C. L. Duurland, E. S. Jordanova, J. J. van Ham, I. Ehsan, S. L. van Egmond, M. J. P. Welters and S. H. van der Burg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:14

    Published on:

  48. Content type: Research article

    The tumor microenvironment (TME) is a complex mixture of tumor epithelium, stroma and immune cells, and the immune component of the TME is highly prognostic for tumor progression and patient outcome. In lung c...

    Authors: Katey S. S. Enfield, Spencer D. Martin, Erin A. Marshall, Sonia H. Y. Kung, Paul Gallagher, Katy Milne, Zhaoyang Chen, Brad H. Nelson, Stephen Lam, John C. English, Calum E. MacAulay, Wan L. Lam and Martial Guillaud

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:13

    Published on:

  49. Content type: Research article

    Chemoradiotherapy (CRT) remains one of the most common cancer treatment modalities, and recent data suggest that CRT is maximally effective when there is generation of an anti-tumoral immune response. However,...

    Authors: Aurelie Hanoteau, Jared M. Newton, Rosemarie Krupar, Chen Huang, Hsuan-Chen Liu, Angelina Gaspero, Robyn D. Gartrell, Yvonne M. Saenger, Thomas D. Hart, Saskia J. Santegoets, Damya Laoui, Chad Spanos, Falguni Parikh, Padmini Jayaraman, Bing Zhang, Sjoerd H. Van der Burg…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:10

    Published on:

  50. Content type: Research article

    Toll-like receptor 9 agonists are potent activators of the immune system. Their clinical potential in immunotherapy against metastatic cancers is being evaluated across a number of clinical trials. TLR9 agonis...

    Authors: Kerstin Kapp, Barbara Volz, Michael A. Curran, Detlef Oswald, Burghardt Wittig and Manuel Schmidt

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:5

    Published on:

Annual Journal Metrics

Advertisement